Phaseline

Companies › Skye Bioscience

Skye Bioscience: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nimacimab
Cannabinoid CB1 receptor negative allosteric modulator
CNR1Phase 2ObesityNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06577090NimacimabPhase 2ObesityMetabolic and endocrineNov 2026
NCT06577090NimacimabPhase 2ObesityMetabolic and endocrineNov 2026

From the company's SEC filings

Cash and short-term investments of $10m on 2026-06-30; operating cash outflow about $32m a year; runway about 4 months at that burn, to Oct 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CNR1 (1)

Companies with the same targets

Jazz Pharmaceuticals IGC Pharma Sinfatin Zynerba Pharmaceuticals PleoPharma Laboratorio Elea Phoenix Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed

Companies built like this

Veru Actimed Therapeutics PolTREG Protalix Verdiva Bio Dev

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.